Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
05.08. | BMS and Bain Capital launch new company to develop immunology therapies | ||
05.08. | CHMP recommends BeOne Medicines' Tevimbra for new lung cancer indication | ||
05.08. | Solving the patient engagement value equation | ||
04.08. | Biogen's Qalsody granted MHRA approval to treat rare form of motor neurone disease | ||
04.08. | FDA grants fast track designation to Nektar's rezpegaldesleukin in alopecia areata | ||
04.08. | The power of representation, innovation and trust in rare disease clinical trials | ||
01.08. | Sanofi's Sarclisa approved by EC to treat newly diagnosed multiple myeloma | ||
01.08. | Eli Lilly's Alzheimer's disease drug donanemab recommended by CHMP | ||
01.08. | Patient engagement - a journey of health activation | ||
31.07. | Merck unveils $3bn cost-cutting plan to support pipeline and new product launches | ||
31.07. | Havas Lynx appoints Talin Apkarian as Havas Lynx Hudson managing director | ||
30.07. | Moderna's LP.8.1-adapted COVID-19 vaccine recommended by CHMP | ||
30.07. | Havas Lynx appoints Ayesha Walawalkar as chief strategy officer | ||
29.07. | AstraZeneca's Imfinzi granted FDA priority review to treat early-stage gastric cancer | ||
29.07. | Roche shares promising data from Alzheimer's disease development portfolio | ||
28.07. | AbbVie's Elahere granted MHRA approval to treat platinum-resistant ovarian cancer | ||
28.07. | J&J announces EC approval of Imbruvica in previously untreated mantle cell lymphoma | ||
25.07. | Novartis and Matchpoint enter inflammatory disease partnership worth $1bn | ||
25.07. | GSK's Blenrep combinations granted EC approval for relapsed/refractory multiple myeloma | ||
25.07. | Sanofi and Kling Bio partner to accelerate discovery of neutralising antibodies | ||
24.07. | Johnson & Johnson's Darzalex approved by EC as first treatment for high-risk SMM | ||
24.07. | LEO's Anzupgo granted FDA approval to treat moderate-to-severe chronic hand eczema | ||
24.07. | Abivax shares positive late-stage results for obefazimod in ulcerative colitis | ||
23.07. | AstraZeneca unveils plans to boost US footprint with $50bn investment | ||
23.07. | Roche's Itovebi granted EC approval to treat advanced breast cancer patients |